BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

LD-2 disclosure · 1st Quarter - Report

INTERCEPT PHARMACEUTICALS

via AMERICAN CAPITOL GROUP

1st Quarter (Jan 1 - Mar 31) · 2023Posted Apr 18, 2023Filing document ↗LDA record ↗

Income$30Kfee reported

Client

Name: INTERCEPT PHARMACEUTICALS
Description: Pharmaceutical Company
Location: New Jersey · United States of America

Registrant

Firm: AMERICAN CAPITOL GROUP
Description: Government Relations Firm
Location: Annandale, Virginia, United States of America

Lobbying activities

1 issue

Health Issues
FDA Issues
LobbyistsDAVE LARSON
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

INTERCEPT PHARMACEUTICALS — Lobbying — Receipts Report